MARKET

MNOV

MNOV

Medicinova
NASDAQ
1.440
-0.030
-2.05%
After Hours: 1.450 +0.01 +0.71% 16:05 05/12 EDT
OPEN
1.470
PREV CLOSE
1.470
HIGH
1.480
LOW
1.427
VOLUME
6.49K
TURNOVER
--
52 WEEK HIGH
2.550
52 WEEK LOW
1.120
MARKET CAP
70.62M
P/E (TTM)
-6.3906
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MNOV last week (0505-0509)?
Weekly Report · 12h ago
MediciNova Inc <MNOV.OQ> expected to post a loss of 14 cents a share - Earnings Preview
Reuters · 6d ago
Weekly Report: what happened at MNOV last week (0428-0502)?
Weekly Report · 05/05 10:32
Weekly Report: what happened at MNOV last week (0421-0425)?
Weekly Report · 04/28 10:38
Weekly Report: what happened at MNOV last week (0414-0418)?
Weekly Report · 04/21 10:38
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
Barchart · 04/14 18:00
Weekly Report: what happened at MNOV last week (0407-0411)?
Weekly Report · 04/14 10:31
MediciNova Is Maintained at Buy by D. Boral Capital
Dow Jones · 04/09 11:27
More
About MNOV
More
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Recently
Symbol
Price
%Change

Webull offers Medicinova Inc stock information, including NASDAQ: MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.